HK Stock Market Move | TYK MEDICINES-B(02410) rose nearly 15%, reaching a strategic cooperation with Qilu Pharmaceutical to accelerate the commercialization of TY-9591.

TYK Medicines-B(02410) opened nearly 15% higher, as of the time of writing, rose by 14.96%, to 9.68 Hong Kong dollars, with a trading volume of 3.238 million Hong Kong dollars. In terms of news, on July 21st, Tongyu Kang Medicine and Qilu Pharmaceutical or its designated affiliates reached a licensing and cooperation agreement as well as a supply and commercialization agreement. They will work together to develop, produce, and commercialize TY-9591 active pharmaceutical ingredient in mainland China. Meanwhile, Qilu Pharmaceutical will also invest in Tongyu Kang Medicine, and the two parties will establish a deep strategic partnership. Through this cooperation, Tongyu Kang Medicine will have the right to receive 700 million yuan in share subscription fees and upfront cash payments, as well as up to 2.06 billion yuan in milestone payments for regulatory approval and indication expansion of TY-9591. It is worth noting that the new drug application (NDA) for TY-9591 was formally accepted by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration in early 2026, and was included in the priority review and approval program. Currently, it is in the NDA review stage. Once approved for marketing, TY-9591 is expected to provide a better treatment option for a large number of EGFR-mutant NSCLC patients, further meeting the clinical unmet needs.